-+ 0.00%
-+ 0.00%
-+ 0.00%

D. Boral Capital Maintains Buy on ImmunityBio, Maintains $24 Price Target

Benzinga·12/12/2025 12:45:17
Listen to the news
D. Boral Capital analyst Jason Kolbert maintains ImmunityBio (NASDAQ:IBRX) with a Buy and maintains $24 price target.